Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 1018-1025

  Folprecht, G ^a   Gruenberger, T ^b   Bechstein, W ^c   Raab, H R ^d   Weitz, J ^a   Lordick, F ^e   Hartmann, J T ^f   Stoehlmacher Williams, J ^a   Lang, H ^g   Trarbach, T ^h   Liersch, T ⁱ   Ockert, D ^j   Jaeger, D ^k   Steger, U ^l   Suedhoff, T ^m   Rentsch, A ^a   Kohne C H ^d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GOETHE UNIVERSITY   (Germany)

^d KLINIKUM OLDENBURG   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ UNIVERSITY OF GÖTTINGEN   (Germany)

^j KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^m Klinikum Passau   (Germany)

more..

Author keywords

cetuximab; chemotherapy; colorectal cancer; liver metastases; multidisciplinary treatment; resection

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84904904651     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu088     Document Type: Article

References (22)

1. Morris, E.J., Forman, D., Thomas, J.D., et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 97 (2010), 1110–1118.
2. Van Cutsem, E., Köhne, C.H., Lang, I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29 (2011), 2011–2019.
3. Bokemeyer, C., Bondarenko, I., Hartmann, J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22 (2011), 1535–1546.
4. Folprecht, G., Grothey, A., Alberts, S., et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005), 1311–1319.
5. Folprecht, G., Lutz, M., Schöffski, P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17 (2006), 450–456.
6. Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010), 38–47.
7. Nordlinger, B., Sorbye, H., Glimelius, B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008), 1007–1016.
8. Ye, L.C., Liu, T.S., Ren, L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31 (2013), 1931–1938.
9. Maughan, T.S., Adams, R.A., Smith, C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377 (2011), 2103–2114.
10. Tveit, K.M., Guren, T., Glimelius, B., et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30 (2012), 1755–1762.
11. Douillard, J.Y., Oliner, K.S., Siena, S., et al. Panitumumab FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034.
12. Lam, V.W., Pang, T., Laurence, J.M., et al. A systematic review of repeat hepatectomy for recurrent colorectal liver metastases. J Gastrointest Surg 17 (2013), 1312–1321.
13. Alberts, S.R., Horvath, W.L., Sternfeld, W.C., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II Study. J Clin Oncol 23 (2005), 9243–9249.
14. Adam, R., Wicherts, D.A., de Haas, R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 27 (2009), 1829–1835.
15. Chibaudel, B., Maindrault-Goebel, F., Lledo, G., et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27 (2009), 5727–5733.
16. Adams, R.A., Meade, A.M., Seymour, M.T., et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12 (2011), 642–653.
17. Weeks, J.C., Catalano, P.J., Cronin, A., et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367 (2012), 1616–1625.
18. Mende, M., Trautmann, K., Rentsch, A., et al. Patients’ perspectives on palliative chemotherapy of colorectal and non-colorectal cancer: a prospective study in a chemotherapy-experienced population. BMC Cancer, 13, 2013, 66.
19. Rees, M., Tekkis, P.P., Welsh, F.K., et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247 (2008), 125–135.
20. Spelt, L., Andersson, B., Nilsson, J., et al. Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review. Eur J Surg Oncol 38 (2012), 16–24.
21. Folprecht, G., Schuette, K., Stoehlmacher, J., et al. Cetuximab and FOLFOXIRI: dose-escalation study in previously untreated patients with metastatic colorectal cancer. Proc Gastrointest Canc Symp (ASCO/AGA/ASTRO/SSO), 2010 abstract 480.
22. Falcone, A., Cremolini, C., Masi, G., et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group. J Clin Oncol (Meeting Abstracts), 31, 2013, 3505.